 Takeda Pharmaceutical Co Ltd NYSE: TAK announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did not achieve the pre-defined statistical significance for the primary endpoint of event-free survival EFS. 